BioHarvest Sciences Issues Year End Shareholder Letter
Rhea-AI Summary
BioHarvest Sciences (NASDAQ: BHST) issued a year-end letter reporting an annualized revenue run rate exceeding US$36 million, gross margins above 60%, and a plan to reach adjusted EBITDA breakeven in the near term. The company reported >85,000 active VINIA users, >90% subscription purchase rate, and 10,000+ verified reviews at a 4.7/5 average rating.
Operational highlights include VINIA Blood Flow Hydration launched in-market, CDMO contract wins in May and October 2025 (including a 25% ownership stake in a saffron-derived compound), AI-enabled discovery services, and a planned 100-ton manufacturing footprint. BioHarvest raised approximately $30.8 million in 2025 to fund growth and manufacturing expansion.
Positive
- Revenue run rate > US$36 million
- Gross margin above 60%
- VINIA active users >85,000 with >90% subscription purchases
- Raised approximately $30.8 million in 2025 financing
- 25% ownership stake in saffron-derived final compound
- Planned 100-ton manufacturing footprint at corporate campus
Negative
- None.
News Market Reaction
On the day this news was published, BHST gained 3.72%, reflecting a moderate positive market reaction. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $127M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BHST fell 3.14% while peers were mixed: LFVN +2.14%, FTLF +1.45%, DDC +13.22%, ABVE -2.19%, HAIN -0.9%, suggesting stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Government grant | Positive | +1.1% | $1.6M IIA grant to fund second-generation Botanical Synthesis platform. |
| Dec 03 | Product launch | Positive | +3.0% | Launch of VINIA Blood Flow Hydration into $13B U.S. electrolyte market. |
| Nov 13 | Earnings update | Negative | -7.6% | Q3 results with net loss of $2.5M and cautious adjusted EBITDA range. |
| Nov 12 | Investor conference | Positive | +14.8% | Conference participation highlighting growth, new VINIA products, and CDMO wins. |
| Nov 10 | Equity offering | Negative | +2.5% | Closing of $19.9M upsized public equity offering at $7.00 per share. |
Across the last five news events, BHST showed mostly aligned price reactions, with one divergence on a public offering announcement.
Over the past few months, BioHarvest reported Q3 2025 revenue of $9.1M with 61% gross margin and a net loss of $2.5M, while guiding Q4 revenue to $9.0–9.5M. It closed an upsized $19.9M offering and later secured a $1.6M Israeli Innovation Authority grant to advance its Botanical Synthesis™ platform. The company launched VINIA Blood Flow Hydration into the $13B U.S. electrolyte market. Today’s shareholder letter extends this trajectory, emphasizing an annualized revenue run rate above $36M, >60% gross margins, and balance sheet strengthening.
Market Pulse Summary
This announcement outlines BioHarvest’s first full year on Nasdaq, highlighting an annualized revenue run rate above $36M, gross margins over 60%, and more than 85,000 active VINIA users with over 90% subscription-based sales. Management details balance sheet strengthening via roughly $30.8M of 2025 financing and a planned 100‑ton manufacturing footprint. Compared with recent product launches and a government grant, this letter synthesizes progress, while future monitoring may center on adjusted EBITDA breakeven and scaling the CDMO pipeline.
Key Terms
botanical synthesis technical
cdmo services financial
adjusted ebitda financial
piceid resveratrol medical
nutraceutical medical
AI-generated analysis. Not financial advice.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.
Dear Fellow Shareholders,
2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue run rate exceeding US
D2C Products Business - A Year of Expanding our Portfolio and Active Customer Base
Our D2C Products business, led by the VINIA® brand, has continued its path of aggressive growth and product diversification. The 'VINIA Inside' strategy is allowing us to capitalize on our growing brand awareness and market penetration to expand the demographic reach of our products. Whether it is VINIA capsules, Hot Beverages, Blood Flow Hydration, or Daily Chews, each of these products broadens our demographic reach and positions VINIA at the intersection of major growing consumer trends in the areas of longevity, vitality, cognitive health, and overall healthy living.
Our VINIA Blood Flow Hydration Solution has now been "in market" for 6 weeks and is already being recognized by consumers as a breakthrough concept in the category: the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol, designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. Consumer feedback has been overwhelmingly positive from an efficacy and taste perspective and 2026 will see us double down from an investment perspective on this unique product and delivery system which we believe can deliver significant incremental revenue for the business as we strive to gain our fair share of the
Our total VINIA® active users now exceed 85,000, a testament to the efficacy of VINIA and for potential future BioHarvest products as well. More than
CDMO Services Division: A Year of Capability Building and Onboarding Major New Life-Changing Compounds
Our CDMO Services division in 2025 reached a critical inflection point. During the year, we secured anchor partnerships across pharmaceuticals, nutrition, fragrance, and nutraceuticals, validating the commercial relevance of our Botanical Synthesis platform. We advanced multiple customer programs through defined R&D stages, expanded yields and tissue-culture capabilities, and introduced new AI-enabled discovery services. These efforts not only generate milestone-based revenues, but also steadily increase the long-term value of our platform.
This year saw the CDMO business commence work on 2 major new plant-based compounds, both of which are in high demand in multi-billion-dollar industries. In May 2025, we secured a new contract to develop a plant-based fragrance compound derived from a plant species that is under significant threat due to overharvesting and habitat loss and whose biological material supports a multi-billion-dollar segment of the Premium Fragrance Industry. In October, we announced a new contract with Saffron Tech, with the goal of developing a "super" saffron-derived compound using our Botanical Synthesis technology. Given the size of this opportunity, we secured a
Strengthening our Balance Sheet to Drive Further Growth Momentum
Operationally and financially, 2025 was also a year of strengthening. We significantly improved our balance sheet, raising approximately
Overall, our first year on Nasdaq has resulted in increased analyst coverage and significant increases in both daily trading volume and our overall U.S. investor base, which are important building blocks to achieving a fair market valuation. Our conviction remains that continued execution, growing revenues, and improved profitability will ultimately attract a broader and more stable investor base and reward our shareholders accordingly.
Final Thoughts
Bioharvest Sciences enters this New Year in a position of strength - with growth momentum, strong core fundamentals, and expanded scientific capabilities. Following our successful financing, we are now fully funded, which allows us to focus on our operational objectives, and to make strategic capital investments to support aggressive growth and expansion, including the development of our new corporate campus and expanded manufacturing facility, as well as the advancement of critical innovation across our end-to-end business.
BioHarvest today is a company with two complementary growth engines, operating in large and attractive markets, supported by proprietary technology and improving financial strength. We believe our performance and results will increasingly speak for themselves — and that over time, the market will reflect that value.
Looking ahead, our priorities are clear: accelerate revenue growth, expand margins, and reach adjusted EBITDA breakeven, while continuing to execute against a growing CDMO pipeline and an expanding VINIA product ecosystem. Our vision continues to unfold, and our confidence in the company's strategy, technology, and people has never been stronger.
On behalf of the management team and Board of Directors, thank you for your continued support and confidence.
Best Wishes,
Ilan Sobel
About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is not certain, may take significant time, and is subject to risks and uncertainties beyond company control such as consumer preferences, competition landscape, government approvals required for sale or import, acceptance of benefit claims, and marketing budgets of the company and its competitors. There is no assurance that the Company will maintain or improve current financial performance or achieve adjusted EBITDA profitability in a specified time frame, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Contacts:
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279690
FAQ
What revenue run rate did BioHarvest (BHST) report in the January 7, 2026 shareholder letter?
What gross margins did BioHarvest (BHST) disclose for 2025?
How many active VINIA users did BioHarvest (BHST) report and what is the subscription rate?
How much financing did BioHarvest (BHST) raise in 2025 and by what methods?
What CDMO deals did BioHarvest (BHST) announce in 2025 and what ownership interest was secured?
What manufacturing expansion did BioHarvest (BHST) outline in the shareholder letter?
What near-term financial milestone did BioHarvest (BHST) set in the letter?
